For almost two years, the loudest voices on puberty blockers in Australia have been politicians and newspaper columnists. On Monday, the country’s peak medical research body finally weighed in, and its answer was clear: blockers should stay on the table for some trans young people.
Within hours, Queensland and the Northern Territory said they weren’t changing a thing.
The short version
- Who: The National Health and Medical Research Council (NHMRC), Australia’s leading body for health research funding and evidence-based guidance.
- What: Interim advice making a conditional recommendation for puberty blockers for young people with gender incongruence who have started puberty and been assessed as suitable.
- How: Through shared decision-making between the young person, their parents or carers, and clinicians.
- The catch: It’s advisory. Queensland and the NT both rejected it on day one.
- Next: Public feedback is open until January 18, 2027. Full guidelines are due in 2028.
What the advice actually says
The recommendation comes from the NHMRC’s Gender Guidelines Development Committee, according to ABC News. It applies to young people with gender incongruence, “with or without distress,” who have begun puberty and been assessed as suitable for treatment.
The committee was careful not to treat every young person the same. “Not all young people will want or need the same intervention at the same time or age,” it wrote, as quoted by the ABC.
The advice describes blockers as “one possible part of care,” newsGP reported, and it explicitly pushes back on “wait and see.” Holding off, it warns, “can affect the young person’s physical and mental health, wellbeing, and ability to function,” as PinkNews quoted.
“Young people and their families should be able to have informed discussions with their healthcare professionals,” said NHMRC Acting Chief Executive Prue Torrance, per newsGP.
Honest about the evidence
This isn’t a victory lap, and the NHMRC doesn’t pretend it is. The review behind the advice included 15 non-randomised studies, mostly following young people for six months to two years, the ABC reported. Overall certainty of evidence was rated low.
Within that, reviewers found blockers may improve psychosocial functioning and may reduce suicidality behaviours. They found no eligible evidence on fertility, fractures or other bone health measures, and said serious adverse events appear rare but young people should be monitored.
That’s exactly why the recommendation is “conditional.” The committee said conditional recommendations fit when shared decision-making is essential and evidence certainty is low. “Both are the case here,” the report said.
Federal Health Minister Mark Butler made a similar point, noting to SBS News that guidelines for pregnancy, dementia, arthritis and stroke care carry the same kind of caveats. Low-certainty evidence is common in medicine. Banning a treatment because of it is not.
Queensland and the NT: “unchanged”
Queensland became the first state to restrict access, banning public hospitals from prescribing gender-affirming hormone treatments in January 2025, SBS reported. When the Supreme Court overturned the ban in October 2025, finding officials hadn’t properly consulted before the original directive, the government reinstated it within hours.
On Monday, Health Minister Tim Nicholls said the state had run its own independent review and that its position “remains unchanged and we will continue to prioritise the health, safety and wellbeing of young Queenslanders.” The ABC reports Queensland plans to keep its pause until 2031, pending the UK’s Pathways trial.
The Northern Territory, which announced in December 2025 that it would stop funding puberty blockers and hormone treatments for children, also said its position was unchanged. A spokesperson told Nine Newspapers that Queensland, the UK and Finland “have all taken a cautious approach,” SBS reported.
Canberra can’t overrule them
Butler commissioned the NHMRC review in 2025, two days after Queensland’s ban. He said he’d rather the issue go to experts “rather than have debate settled by commentators in our big newspapers,” per SBS.
But he was also clear that the Commonwealth can’t force the states’ hand. “Every state government, no matter their political persuasion, will consider the advice,” he said, as quoted by PinkNews.
Who’s saying what
- Equality Australia CEO Anna Brown said the advice “reinforces that the care trans young people are receiving in Australia today is grounded in evidence.”
- The Greens’ David Shoebridge: “This seems like a very credible policy.”
- Liberal senator Andrew Bragg said trans people shouldn’t be used as a “political football,” and that blockers can be appropriate in rare cases.
- One Nation said it would fight to ban the treatment.
(All via SBS News.)
Why this matters beyond Australia
Australia now joins a short but growing list of places where expert bodies or courts have pushed back on blanket bans. Earlier this year, New Zealand’s High Court ruled its ban on new prescriptions unlawful, so doctors there can prescribe again. The UK, Finland and many US states have gone the other way.
For trans young people in Queensland and the NT, Monday didn’t change what happens at the clinic. What it changed is the argument. The most authoritative medical voice in the country has now said, carefully and with the caveats on display, that families and doctors should be allowed to make this call together.
What happens next
- Until January 18, 2027: Public consultation on the interim advice, via the NHMRC’s website.
- 2028: Full national guidelines covering wider care for trans and gender-diverse people under 18.
- Watch: Whether any other state or territory moves, and whether Queensland’s own review gets a second look.
Sources: ABC News (Nov 16, 2026); SBS News (Nov 16, 2026); newsGP / RACGP (Nov 16, 2026); PinkNews (Nov 16, 2026). Photo: yasmin peyman on Unsplash.